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Natural products isolated from plants of the Phyllanthus genus, specifically 
members of the arylnaphthalene subclass of lignan lactones, show promise as a potential treatment 
option for ovarian cancer. These compounds are worth examining further because several 
structurally related synthetic analogues have displayed highly potent cytotoxic 
activities against ovarian cancer cell lines in the nanomolar range. Our lead compound, PHY34, 
exerts its cytotoxic effects by inhibiting autophagy in ovarian cancer cells which is followed by 
apoptotic cell death. Potent experimental agents with attractive mechanisms of action, including 
autophagy modulators, are needed to continue to fight cancer, potentially overcoming the problem 
of chemoresistance and increasing the chances of survival for patients.  
In order to further assess and obtain structure-activity relationship data for this class of 
compounds, several new analogues were synthesized by modifying the D-ring on the diphyllin 
core of the phyllanthusmins. The diphyllin precursors, representing the core ring system, were 
synthesized using a five-step method with 3,4-dimethoxybenzaldehyde as the precursor. At that 
stage, the sugar moiety could then put on at the C7 position to complete the synthesis of the 
derivatives. A total of six analogues with D-ring modifications were made, and characterization 
data was collected for both the diester and diphyllin precursors to confirm the structural 
assignments. This included collection of both proton and carbon NMR spectra for each 
compound for a total of twelve proton NMR spectras and twelve carbon NMR spectras as well as 
the determination of their accurate masses using mass spectrometry. Biological data for four of 
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1.1 Cancer Disease State 
 
Cancer is a disease characterized by abnormal cell growth which can then spread to other 
organs and areas of the body in a process known as metastasis.1 In normal healthy cells of the 
body, the cell cycle, the process in which cells replicate DNA and divide into two identical 
daughter cells, is tightly regulated by checkpoints in the G1 phase, the G2 phase, and the 
metaphase. Dysfunctions in the checkpoints can cause premature cell death or cell cycle 
reprogramming which can eventually lead to tumor growth.2 These tumors then become 
classified as malignant when they start to spread to other parts of the body. 
The causes of cancer include both genetic and external factors. According to the National 
Cancer Institute at the National Institutes of Health, inherited genetic mutations are a significant 
factor in about 5 to 10 percent of all cancers.3 External factors, known as carcinogens, may 




include physical, chemical, and biological agents or exposures. For example, high-energy 
radiation such as x-rays and gamma rays are physical carcinogens that can cause damage to 
DNA and disrupt the normal processes of the cell cycle. Chemical carcinogens such as 
formaldehyde and those found in tobacco smoke can also lead to DNA damage. Certain 
infectious agents like human papillomavirus and hepatitis B virus are biological carcinogens that 
can cause cancer through a variety of factors including disrupting the cell cycle, weakening the 
immune system, and causing chronic inflammation.4 
There are many different types of cancer, 
and they are named based on where the cancer 
originated. Ovarian cancer first develops in the 
ovaries of the female reproductive system or in 
the surrounding fallopian tubes and peritoneum 
lining.1 All women have a risk of developing 
ovarian cancer, but there are also several 
factors that could increase the risk including 
having a mutation in the BRCA1or BRCA2 gene, taking estrogen by itself for more than ten 
years, and having close family members that have had ovarian cancer.1 Ovarian cancer is 
assigned a stage from I to IV depending on the size of the tumor, the spread to nearby lymph 
nodes, and the spread to distant sites with stage IV being the most severe.4 The symptoms of 
ovarian cancer include vaginal bleeding, abdominal pain, bloating, and trouble eating.3 These 
symptoms do not seem serious in themselves, but, if left untreated, ovarian cancer can spread to 
other organs such as the spleen or liver and shut down important biological processes which can 
lead to death. 






 Rates of new cases of cancer in the United States according to data from the Centers for 
Disease Control and Prevention (CDC) is detailed in Figure 1.3 and 1.4. They show that 
1,633,390 new cases of cancer were reported in 2015, and 595,919 people died of cancer. Of 
those reported cases, 21,429 were new cases of ovarian cancer, and 13,920 women died of 
ovarian cancer.6 The five-year relative survival rate for all cancer patients is 65.6%, but that 
percentage drops to 46.1% for patients with ovarian cancer specifically.6 
 
 






The World Health Organization (WHO) claims that 30-50% of cancer deaths could be 
prevented if patients modified certain aspects of their lifestyles such as maintaining a healthy 
body weight, exercising regularly, avoiding tobacco smoke, and reducing alcohol consumption.7 
Nonetheless, cancer continues to claim millions of lives globally. WHO has identified cancer as 
the world’s second leading cause of death and has estimated that it is the cause of 9.6 million 
deaths in 2018.7 As more and more cases arise each year, is has become necessary to look for 
new ways to combat this serious problem. 










Figure 1.5. Some current widely used chemotherapeutics for the treatment of ovarian cancer.8 
 
The primary therapeutic approach for patients with advanced cancer progression during 
their initial diagnosis is cytoreductive surgery followed by a combination of platinum-based and 
taxane-based chemotherapy. First-line treatment is initially effective with many patients who 
achieve complete remission, but up to 80% of these patients also experience relapse due to 
rapidly developed chemoresistance.8 Maintenance therapy with drugs such as bevacizumab, a 
recombinant monoclonal antibody with antiangiogenic properties, and olaparib, a PARP, poly 
ADP ribose polymerase, inhibitor, have been used in clinical trials in order to assess their 
effectiveness against recurrent ovarian cancer. However, the results have shown that cumulative 
toxicity is a major issue with maintenance therapy, and it does not provide clinically significant 
increases in survival benefits.9  
There are a great number of anticancer drugs because of the wide variety of biological 
targets that can be exploited in cancer cells and their life cycles as shown in Figure 1.6. 
Paclitaxel, shown in Figure 1.5, is a member of the taxane class of molecules. It exerts its 
antitumor properties by stabilizing microtubule polymers in cancer cells which subsequently 
arrests cells in the metaphase and prevents them from further replicating.10 Olaparib has a 







DNA repair.11 As patients continue to develop chemoresistance towards the current approved 
drugs on the market, there is an urgent need to develop new drugs with novel mechanisms of 
























































Chapter 2: Antiproliferative Activity of the Phyllanthusmin Class of Arylnaphthalene 

























Discoveries in natural products have led to breakthroughs in cancer chemotherapy. The 
arylnaphthalene subclass of lignan lactones represents a relatively recently discovered 
chemotype that has been found to possess potent cytotoxicity toward human cancer cell lines. 
For example, both justicidin A (Figure 2.1), a methylated diphyllin derivative, and 
acutissimalignan A, a diphyllin methylated arabinoside derivative, exhibited cytotoxicity towards 













acutissimalignan A                      
Figure 2.1. Two examples of cytotoxic arylnaphthalene lignan lactones 
 
           The phyllanthusmins, which are also members of the arylnaphthalene subclass of lignan 
lactones, are natural products isolated from plants from the 
Phyllanthus genus. Species from this genus have been 
utilized in traditional Asian medicine for their anticancer, 
antiviral, and insecticidal properties.15 Phyllanthus poilanei 
samples, shown in Figure 2.2, were collected in South Figure 2.2 Phyllanthus poilanei 












Vietnam by Dr. Doel Soejarto between 2004 and 2011 as a part of a P01 grant. Dr. A. Douglas 
Kinghorn (Division of Medicinal Chemistry & Pharmacognosy, OSU College of Pharmacy) and 
his lab were then able to isolate two novel (1 and 2 in Figure 2.3) and four known (3-6 in Figure 
2.3) arylnaphthalene lignan lactones from the chloroform-soluble extract using a bioassay guided 
fractionation approach against HT-29 colon carcinoma cells. As a part of these studies, diphyllin 
(8) and the semisynthetic derivative (7) were also made and evaluated for their activity against 
HT-29 human colon cancer lines.16 This data is shown in Figure 2.4. From a structural 
perspective, all of the isolated compounds in this series possess the diphyllin core ring system, 
although phyllanthusmin A (6) lacks a methyl group at the C4 position. In addition, compounds 
1-5 have a sugar moiety attached to the C7 phenolic oxygen atom of diphyllin. For the 
phyllanthusmins B-E (1-4) this is a substituted arabinose ring, while for cleistanthin B (5), this is 

















                    Compound                                                                             HT-29 
 
                              1                               0.17    
      2                                           1.8       
      3                     1.8    
      4                     3.2     
      5                   12.2 
      6         >10 
      7                              0.11 
        8          7.6 
        Paclitaxel*               0.001 
______________________________________________________________________________ 
Figure 2.4 Cytotoxicity of compounds isolated and derived from chloroform-soluble extract of Phyllanthus 
poilanei toward H-29 cells. * FDA approved anticancer drug paclitaxel was used as a positive control.16 
  
Previous published studies pertaining to other arylnaphthalene compounds similar in 
structure to the phyllanthusmins have revealed the importance of the glycosidic sugar moiety to 
the antiproliferative properties of this class of lignans.17,18,19 Diphyllin glycosides such as 
phyllanthusmins B-E16 and D1119 have been shown to possess more potent in vitro activity 
against cancer cell lines than their aglycone, diphyllin, alone. Based on this knowledge of the 
influence of the sugar moiety for potent antiproliferative activity, 
the graduate students in the Fuchs lab have previously 
synthesized a number of different glycone analogues as well as 
C-ring lactone analogues to further explore the structure-activity 
relationships of the phyllanthusmins. The results they gathered 
led to the conclusion that substituted (acetylated or methylated) 
hydroxy groups on the sugar moieties, as opposed to the 
unsubstituted alcohols, and the lactone carbonyl on the 
aglycone are needed for more potent biological activity.20 A modified galactose moiety, PHY34, 


















cell lines and 4.0 nM against OVCAR-8 cell lines.21 In addition to in vitro antiproliferative 
activities, this compound has also been studied in both in vivo hollow fiber and xenograft studies 
in the lab of Dr. Joanna Burdette (Department of Medicinal Chemistry & Pharmacognosy, UIC 
College of Pharmacy). For the xenograft study, OVCAR8-RFP, fluorescently-labeled OVCAR8 
cells, were xenografted intraperitoneally into female mice and monitored by IVIS imaging. Once 
treatment was initiated, the mice were dosed three times a week for three weeks with PHY34 
(0.75 mg/kg) or paclitaxel (5 mg/kg), the positive control. At the completion of the study it was 
shown that PHY34 significantly decreased tumor burden as compared with the vehicle with no 
























Subsequent studies by the Burdette lab have shown that the proposed mechanism of 
action for PHY34 is that it acts as a late-stage autophagy inhibitor which is followed by apoptotic 
cell death.21 This is significant because biomarkers for autophagy, such as Beclin1 and LC3A, 
have been shown to correlate with poor prognosis in certain ovarian cancers which demonstrates 
the potential influence of the autophagic pathway in ovarian cancer.22,23 Combination treatment 
with autophagy inhibitors may also help overcome the problem of disease recurrence and 
chemoresistance in patients with ovarian cancer and increase the chances of survival. The desire 
to further explore the structure-activity relationship of the phyllanthusmins by modifying 
different parts of the compound other than the sugar moiety led to the subsequent synthesis of a 







Figure 2.6 Biological activity of PHY34 in 














































The phyllanthusmins provide a unique opportunity to carry out relatively exhaustive SAR 
studies on a somewhat complex natural product scaffold. This is due in part to the fact that 
elegant synthetic approaches to diphyllin, the aglycone structure, have previously been 
established5. When this project was initiated in the Fuchs lab, a search of the existing 
methodology showed that diphyllin could be readily accessed from simple, commercially 
available starting materials. Subsequent glycosylation of the phenolic oxygen of diphyllin could 
then lead to the phyllanthusmins and a potentially wide range of substituted analogues. 
 
 







Figure 3.1 Charlton reaction scheme with modification to last step to synthesize diphyllin5,20 
 
As connecting the sugar moiety to the diphyllin core via a glycosidic linkage was 
expected to be a relatively straightforward step, the synthesis of phyllanthusmin analogues 
depended on the ability to generate sufficient quantities of diphyllin in an efficient manner. 
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reduction step of the diester to the diphyllin, our lab has been able to produce diphyllin in gram 
scale quantities. The use of 3,4-dimethoxybenzaldehyde as the starting material allowed the 
complete synthesis of diphyllin in just five steps. First, 3,4-dimethoxybenzaldehyde (9) was 
brominated through electrophilic aromatic substitution to afford compound 10. An acetal 
protection step was then performed using ethylene glycol and p-toluenesulfonic acid as the 
catalyst to prevent the n-butyllithium from reacting with the ketone in the subsequent step. 
Compound 11 was then subjected to a lithium-halogen exchange before the slow addition of 
piperonal (12). The intermediate (13) was then immediately subjected to a Diels-Alder reaction 
using acetic acid and diethyl acetylenedicarboxylate. A column chromatography using dry 
loading was performed at this step to obtain the pure diester intermediate (14). The final 
reduction step of the diester to afford diphyllin (15) was performed by adding four equivalents of 
portion-wise lithium aluminum hydride which differs from the reported sodium borohydride 
reduction conditions of Charlton and coworkers. The crude product was finally triturated with 
methanol to cleanly provide diphyllin.  
With the synthesis of diphyllin in hand, we were interested in derivatizing diphyllin to 
explore the role of structural changes, specifically with regard to the substitution of the aromatic 
rings, on biological activity. As mentioned previously, SAR studies in our lab on the 
phyllanthusmins had been limited primarily to modifications of the sugar moiety appended to 
diphyllin. Little was known about the role that the aromatic substituents play in the activity of 
these compounds. Based on the synthetic route employed for the synthesis of diphyllin, we felt 
that the substituents of the D-ring could be varied effectively through replacement of piperonal in 
Figure 3.1 with other appropriately substituted aromatic aldehydes.  
23 
 
 The most significant challenge in the application of this strategy to the synthesis of new 
analogues was the alkylation/Diels-Alder sequence. In this case, the halogen-metal exchange 
reaction with the bromobenzene derivative is highly water sensitive. Based on the fact that the 
newly generated anion can be quenched in the presence of even trace quantities of moisture, the 
reaction is carried out under anhydrous conditions. Furthermore, the addition into the aldehyde 
group leads to the formation of a relatively unstable alcohol. This alcohol cannot be 
chromatographed and is instead taken forward directly to the next step without purification. This 
requires the alkylation reaction to be reasonably clean. The relative conversion of this reaction is 




Figure 3.2 Initial Diels-Alder reaction conditions lead to formation of two products 
 
The subsequent step in this sequence is the Diels-Alder reaction in the presence of diethyl 
acetylenedicarboxylate and acetic acid. In preliminary experiments by Ms. Bernadette Latimer, a 
past undergraduate researcher in the Fuchs lab, it was observed that the desired aromatic product, 
possessing the newly formed aromatic benzene ring, was only formed in low yield. Instead, the 
major product of this reaction was observed to be the bridged bicyclic intermediate shown in 
Figure 3.2 (product B). This bridged bicyclic intermediate is the compound that is formed upon 
initial cycloaddition reaction of the alkyne with the furan intermediate. Under typical reaction 








































Product A Product B
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and elimination reaction to generate the benzene ring. As compared to our synthesis of diphyllin, 
however, on small scale this cycloaddition reaction appears to “stall” prior to the ring opening. 
Subsequent treatment of product B with acid in could promote formation of the aromatic ring 26, 
although this was not very efficient. Based on these results, the reaction conditions were re-
examined and it was found that careful control of the concentration and equivalents of acetic acid 
were critical for the direct formation of the naphthalene system. These analogues could then be 
directed converted to the corresponding lactones through application of the LAH reduction. In this 
way, a series of six D-ring analogues, refer to Figure 3.3, were synthesized. Interestingly, while 
utilizing these conditions for the preparation of the p-anisaldehyde, m-anisaldehyde, and 2-
(benzyloxy)-1,3-dimethoxybenzene D-ring analogues, an additional spot showed up on thin-layer 
chromatography after the Diels-Alder reaction. Spectroscopy data revealed that it was most likely 
excess aldehyde. An additional purification step was needed and performed using 
dimethylformamide and sodium bisulfite before column chromatography.25 This result suggests 
that the Diels-Alder reaction tolerates additional impurities present during the course of the 
reaction. 
 With the diphyllin analogues in hand, these compounds were analyzed using a combination 
of spectroscopic techniques. Most notably, 1H and 13C NMR spectra were obtained for all of the 
compounds in order to confirm the assigned structures. Experimental procedures and NMR 
spectroscopic data are  included in Chapter 4 and the Appendix of this document, respectively. 

















Figure 3.3 Final D-Ring analogues synthesized 
 
Four of the compounds generated in this study were then passed on to Mr. Andrew 
Huntsman in the Fuchs lab for conversion to the glycosides affording PHY-44, PHY-46, PHY-
47, and PHY-48. These glycosides possess the same sugar moiety as PHY-34, namely a 




































































3.2 Biological Studies 
 
Compound                                                           OVCAR-3                        OVCAR-8 
 
PHY-34                0.004         0.004 
PHY-44       0.33       0.0046 
PHY-46          0.93       0.0063 
PHY-47                0.093           0.10 
PHY-48                0.062                    0.027 
Paclitaxel*          7.88           8.05 
Etoposide*       2.89                      8.94 
______________________________________________________________________________ 
 
Figure 3.3 PHY-34 and D-ring analogues and corresponding antiproliferative data in OVCAR-3 and 
OVCAR-8 cell lines expressed as GI50 values in µM. *FDA approved anticancer drugs paclitaxel and 
etoposide were used as reference standards in this experiment. 
 
 
The four final D-ring derivatives with the glycoside of PHY-34, the optimized modified 
galactose moiety, on the C7 position of the diphyllin core were submitted to Dr. Burdette’s lab at 
the University of Illinois at Chicago for biological testing. The results show that PHY-44 and 
PHY-46 exhibited the greatest potencies against the OVCAR-8 cell line while PHY-47 and 
PHY-48 exhibited higher potencies against the OVCAR-3 cell line than the rest of the 
compounds. Interestingly, none of the compounds demonstrated greater than or even equal to the 
potency of PHY-34 against ovarian cancer cell lines. In HT-29 cells (data not shown), however, 
both PHY-44 and PHY-48 were equal to or slightly more potent (~ 2 fold) than PHY-34.  
Overall, this data indicates that the D-ring is very important for the binding of these compounds 
to their biological target(s) and appears to be highly engineered by nature to fit the binding site. 
It is not surprising that PHY-44 shows reasonable potency based on the fact that the hydrogen 
atoms of the methylenedioxy functionality of PHY-34 have been replaced with bioisosteric 
fluorine atoms. The drop in potency for PHY-46 in the OVCAR-3 cell line indicates the 
27 
 
importance of the second oxygen atom in that ring, although PHY-48, which is acyclic and lacks 
the second oxygen atom still retains good potency. One other interesting observation with these 
compounds is that PHY-44 and PHY-46 show significant differences in potencies for the two 
ovarian cancer cell lines (71-fold and 147-fold differences, respectively). These differences were 
seen with many other phyllanthusmin analogues as well, but analogues that closely resemble 
PHY-34 typically showed similar potencies against both of these cell lines. This fact may point 












































































Note: Analogues 14a, 14b, and 14c were first synthesized by Ms. Bernadette Latimer, a past 






2-bromo-4,5-dimethoxybenzaldehyde. To a solution of 3,4-dimethoxybenzaldehyde in 
methanol (1.00 equiv.) was treated with dropwise addition of bromine (1.05 equiv.) and stirred at 
23 °C  for 4 hours. Following completion, the methanol was removed under reduced pressure. 
The solid was then dissolved in DCM and washed with Na2S2O3 then brine. The organic layer 
was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford an 





2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxalane. To a suspension of crude 2-bromo-4,5-
dimethoxybenzaldehyde in toluene (1.00 equiv.) was added ethylene glycol (4.00 equiv.) and p-
toluenesulfonic acid (0.20 equiv.). Using a Dean-Stark apparatus filled with toluene, the reaction 
was refluxed overnight. After cooling to 23 °C, the toluene was removed under reduced pressure. 
The reaction mixture was then dissolved with EtOAc and washed with sodium bicarbonate, 























concentrated under reduced pressure. The crude product was purified via deactivated silica gel 
column chromatography (EtOAc-hexanes, 16:84 → 25:75) to afford 2-(2-bromo-4,5-
dimethoxyphenyl)-1,3-dioxalane as an off-white solid. Spectroscopy data was consist with 








General procedure for arylnaphthalene diester formation: 
To a solution of the acetal in dry THF (0.98 equiv.) was added n-BuLi (2.00 equiv.) and cooled 
to -78 °C. After stirring for 20 minutes, a solution of a substituted benzaldehyde in THF (1.00 
equiv.) was added to the reaction mixture slowly. The reaction was then stirred at -78 °C for an 
additional 30 minutes before slowly letting it warm to 23 °C. After stirring at 23 °C for an 
additional 2 hours, the reaction was quenched with water, and the aqueous layer was extracted 
with EtOAc. The combined organic layers were washed with water and then brine. The organic 
layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford 
a yellow syrup. To a solution of the crude product in DCM (1.00 equiv.) was then added AcOH 
(1.00 equiv.) and diethyl acetylenedicarboxylate (1.00 equiv.). The reaction was stirred at 140 °C 
under reflux overnight. After cooling to 23 °C, the aqueous layer was extracted with DCM. The 














14a Ar = 2,2-difluorobenzo[d][1,3]dioxole
14b Ar = 2,3-dihydrobenzofuran
14c Ar = 2,3-dihydrobenzo[b][1,4]dioxine
14d Ar = 4-methoxyphenyl
14e Ar = 3-methoxyphenyl
14f Ar = 2-(benzyloxy)-1,3-dimethoxybenzene
31 
 
resulting solution was then dried over anhydrous sodium sulfate and concentrated under reduced 
pressure. The crude product was purified via silica gel column chromatography (EtOAc-hexanes, 







Difluorobenzodioxole 14a. Using 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxalane as the 
starting material (0.300 g, 1.04 mmol) and 2,2-difluorobenzo[d][1,3]dioxole-5-carbaldehyde as 
the aldehyde (0.193 g, 1.04 mmol), the above general procedure afforded compound 14a (0.189 
g, 0.375 mmol, 37%) as a yellow oil: 1H NMR (300 MHz, CDCl3) δ 12.47 (s, 1H), 7.75 (s, 1H), 
7.16 – 7.02 (m, 3H), 6.61 (s, 1H), 4.41 (q, J = 7.1 Hz, 2H), 4.05 (s, 3H), 4.17 – 3.93 (m, 2H), 
3.76 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H), 1.02 (t, J = 7.1 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 
170.18, 168.51, 159.95, 152.67, 149.87, 143.45, 143.30, 133.10, 131.73, 129.34, 126.43, 126.11, 
119.89, 112.40, 109.03, 105.28, 102.96, 101.17, 62.11, 60.98, 56.13, 55.87, 29.70, 13.89, 13.71; 


















































Tetrahydrofuran 14b. Using 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxalane as the starting 
material (0.300 g, 1.040 mmol) and 2,3-dihydrobenzofuran-5-carbaldehyde as the aldehyde 
(0.153 g, 1.038 mmol), the above general procedure afforded compound 14b (0.082 g, 0.176 
mmol, 17% yield) as a yellow oil: 1H NMR (300 MHz, CDCl3) δ 12.44 (s, 1H), 7.75 (s, 1H), 
7.17 – 6.81 (m, 3H), 6.76 (s, 1H), 4.65 (td, J = 8.8, 2.6 Hz, 2H), 4.41 (q, J = 7.1 Hz, 2H), 4.06 (s, 
3H), 4.01-3.96 (m, 2H), 3.76 (s, 3H), 3.27 (t, J = 8.5 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H), 1.03 (t, J 
= 7.1 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 170.51, 169.06, 159.75, 159.64, 152.44, 149.79, 
132.69, 130.74, 129.18, 129.14, 128.29, 127.57, 126.76, 119.96, 108.88, 106.11, 102.90, 101.28,  
71.50, 62.05, 60.89, 56.22, 55.92, 29.81, 14.01, 13.95; HRMS-ESI calcd for C26H26O8   (M+Na)+ 









Dioxane 14c. Using 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxalane as the starting material 
(0.300 g, 1.040 mmol) and 2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde as the aldehyde 
(0.170 g, 1.040 mmol), the above general procedure afforded compound 14c (0.105 g, 0.218 























= 8.2 Hz, 1H), 6.85 (d, J = 1.9 Hz, 1H), 6.80-6.76 (m, 2H), 4.39 (q, J = 7.2 Hz, 2H), 4.34-4.26 
(m, 4H), 4.04 (s, 3H), 4.08 – 3.98 (m, 2H), 3.77 (s, 3H), 1.35 (t, J = 7.1 Hz, 3H), 1.05 (t, J = 7.1 
Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 170.49, 168.92, 159.71, 152.47, 149.81, 143.25, 143.20, 
132.35, 130.34, 129.04, 127.65, 124.24, 119.99, 119.94, 116.90, 106.07, 102.88, 101.27, 64.60, 
64.46, 62.07, 60.92, 56.21, 55.95, 14.01, 13.89; HRMS-ESI calcd for C26H26O9   (M+Na)+ 








p-Anisaldehyde 14d. Using 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxalane as the starting 
material (0.500 g, 1.729 mmol) and 4-methoxybenzaldehyde as the aldehyde (0.235 g, 1.729 
mmol), the above general procedure afforded compound 14d (0.128 g, 0.282 mmol, 16%) as a 
yellow oil: 1H NMR (300 MHz, CDCl3) δ 12.45 (s, 1H), 7.74 (s, 1H), 7.24 (d, J = 8.8 Hz, 2H), 
6.97 (d, J = 8.7 Hz, 2H), 6.70 (s, 1H), 4.40 (q, J = 7.2 Hz, 2H), 4.05 (s, 3H), 3.97 (q, J = 7.1 Hz, 
2H), 3.87 (s, 3H), 3.73 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H); 13C NMR (400 
MHz, CDCl3) δ 170.52, 169.05, 159.72, 159.24, 152.48, 149.81, 132.59, 132.12, 129.42, 127.93, 
119.97, 113.57, 106.04, 102.92, 101.29, 62.08, 60.94, 56.24, 55.88, 55.43, 14.03, 13.91; HRMS-




























m-Anisaldehyde 14e. Using 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxalane as the starting 
material (0.500 g, 1.729 mmol) and 3-methoxybenzaldehyde as the aldehyde (0.235 g, 1.729 
mmol), the above general procedure afforded compound 14e (0.112 g, 0.246 mmol, 14%) as a 
yellow oil solid: 1H NMR (300 MHz, CDCl3) δ 12.44 (s, 1H), 7.74 (s, 1H), 7.34 (dd, J = 9.9, 6.2 
Hz, 1H), 6.99 – 6.85 (m, 3H), 6.74 (s, 1H), 4.40 (q, J = 7.2 Hz, 2H), 4.05 (s, 3H), 3.98 (q, J = 7.1 
Hz, 2H), 3.81 (s, 3H), 3.73 (s, 3H), 1.36 (t, J = 7.2 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H); 13C NMR 
(400 MHz, (CD3)2SO) δ 169.78, 150.57, 149.75, 144.93, 142.89, 142.84, 129.54, 129.52, 
128.13, 123.46, 123.42, 121.80, 119.35, 118.58, 116.56, 105.67, 100.83, 66.65, 64.23, 64.13, 


















































2-(benzyloxy)-1,3-dimethoxybenzene 14f. Using 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-
dioxalane as the starting material (0.500 g, 1.729 mmol) and 4-(benzyloxy)-3,5-
dimethoxybenzaldehyde as the aldehyde (0.471 g, 1.729 mmol), the above general procedure 
afforded compound 14f (0.110 g, 0.219 mmol, 13%) as a yellow solid: 1H NMR (300 MHz, 
CDCl3) δ 12.45 (s, 1H), 7.73 (s, 1H), 7.53 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 1.3 Hz, 1H), 7.39 – 
7.27 (m, 3H), 6.75 (s, 1H), 6.55 (s, 2H), 5.12 (s, 2H), 4.40 (q, J = 7.1 Hz, 2H), 4.04 (s, 3H), 3.98 
(q, J = 7.1 Hz, 2H), 3.79 (s, 6H), 3.72 (s, 3H), 1.36 (t, J = 7.1 Hz, 4H), 0.98 (t, J = 7.1 Hz, 3H); 
13C NMR (400 MHz, CDCl3) δ 170.39, 168.91, 159.78, 153.19, 152.53, 149.87, 137.85, 136.08, 
132.74, 132.00, 128.68, 128.66, 128.19, 128.04, 127.97, 119.94, 108.26, 105.87, 102.88, 101.15, 















Note: Analogues 15a, 15b, 15c, 15d, and 15e were first synthesized by Ms. Bernadette Latimer, 








General procedure for lignan lactone formation: 
To a solution of an arylnaphthalene diester dissolved in dry THF (1.00 equiv.) was added lithium 
aluminum hydride (4.00 equiv.) portion-wise at 0 °C. The reaction was warmed to 23 °C over 5 
minutes prior to being cooled back down to 0 °C. It was then quenched dropwise with deionized 
water until the formation of gas was no longer observed. The pH of the reaction was then 
brought down to ~2 by dropwise addition of HCl (2M). The resulting aqueous mixture was then 
extracted with EtOAc. Combined organic layers were washed with brine then dried over 
anhydrous sodium sulfate and concentrated under reduced pressure. The crude solid was 






































14a Ar = 2,2-difluorobenzo[d][1,3]dioxole
14b Ar = 2,3-dihydrobenzofuran
14c Ar = 2,3-dihydrobenzo[b][1,4]dioxine
14d Ar = 4-methoxyphenyl
14e Ar = 3-methoxyphenyl
14f Ar = 2-(benzyloxy)-1,3-dimethoxybenzene
15a Ar = 2,2-difluorobenzo[d][1,3]dioxole
15b Ar = 2,3-dihydrobenzofuran
15c
 Ar = 2,3-dihydrobenzo[b][1,4]dioxine
15d
 Ar = 4-methoxyphenyl
15e Ar = 3-methoxyphenyl




Difluorobenzodioxole lactone 15a. Using difluorobenzodioxane 14a (0.118 g, 0.234 mmol) as 
the starting material, the above general procedure afforded difluorobenzodioxole lactone 15a 
(0.071 g, 0.171 mmol, 73%) as a pale pink solid: 1H NMR (400 MHz, Acetone) δ 9.40 (s, 1H), 
7.72 (s, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.30 (d, J = 1.2 Hz, 1H), 7.19 (dd, J = 8.2, 1.5 Hz, 1H), 
7.02 (s, 1H), 5.39 (s, 2H), 4.01 (s, 3H), 3.73 (s, 3H); 13C NMR (400 MHz, (CD3)2CO) δ 170.34, 
152.28, 151.65, 146.24, 133.22, 130.86, 129.86, 127.45, 124.51, 122.75, 120.26, 113.28, 110.06, 








Tetrahydrofuran lactone 15b. Using tetrahydrofuran 14b (0.082 g, 0.176 mmol) as the starting 
material, the above general procedure afforded tetrahydrofuran lactone 15b (0.039 g, 0.103 
mmol, 59%) as a white powder: 1H NMR (400 MHz, DMSO) δ 7.62 (s, 1H), 7.15 (s, 1H), 7.03 – 
6.97 (m, 2H), 6.85 (d, J = 8.3 Hz, 1H), 5.35 (s, 2H), 4.61 (t, J = 8.6 Hz, 2H), 3.93 (s, 3H), 3.63 
(s, 3H), 3.28 – 3.20 (m, 2H); 13C NMR (400 MHz, DMSO) δ 170.10, 159.36, 150.67, 149.80, 
144.82, 130.64, 130.25, 129.81, 127.50, 127.09, 127.00, 123.62, 121.97, 118.64, 108.50, 105.86, 

























Dioxane lactone 15c. Using dioxane 14c (0.080 g, 0.166 mmol) as the starting material, the 
above general procedure afforded dioxane lactone 15c (0.027 g, 0.068 mmol, 41%) as a white 
powder: 1H NMR (400 MHz, DMSO) δ 10.37 (s, 1H), 7.62 (s, 1H), 6.97 – 6.92 (m, 2H), 6.79 – 
6.73 (m, 2H), 5.35 (s, 2H), 4.31 (d, J = 3.8 Hz, 4H), 3.94 (s, 3H), 3.64 (s, 3H); 13C NMR (400 
MHz, DMSO) δ 169.79, 150.57, 149.76, 144.94, 142.89, 142.84, 129.52, 128.14, 123.46, 123.43, 
121.81, 119.35, 118.58, 116.56, 105.67, 100.83, 66.66, 64.23, 64.13, 55.69, 55.22; HRMS-ESI 







p-Anisaldehyde lactone 15d. Using p-anisaldehyde 14d (0.370 g, 0.814 mmol) as the starting 
material, the above general procedure afforded p-anisaldehyde lactone 15d (0.137 g, 0.374 
































2H), 7.07 – 7.01 (m, 2H), 6.95 (s, 1H), 5.37 (s, 2H), 3.95 (s, 3H), 3.85 (s, 3H), 3.63 (s, 3H); 13C 
NMR (101 MHz, DMSO) δ 169.77, 158.58, 150.45, 149.64, 144.83, 131.67, 129.80, 129.50, 
127.11, 123.38, 121.79, 118.52, 113.27, 105.53, 100.81, 66.58, 55.61, 55.06, 55.03; HRMS-ESI 







m-Anisaldehyde lactone 15e. Using m-anisaldehyde 14e (0.250 g, 0.550 mmol) as the starting 
material, the above general procedure afforded m-anisaldehyde lactone 15e (0.105 g, 0.287 
mmol, 52%) as a white powder: 1H NMR (300 MHz, DMSO) δ 10.41 (s, 1H), 7.63 (s, 1H), 7.39 
(t, J = 7.9 Hz, 1H), 7.04 – 6.97 (m, 1H), 6.91 – 6.82 (m, 3H), 5.36 (s, 2H), 3.93 (s, 3H), 3.76 (s, 
3H), 3.60 (s, 3H); 13C NMR (400 MHz, DMSO) δ 169.56, 158.74, 150.50, 149.71, 145.01, 
136.64, 129.17, 128.86, 123.27, 122.70, 121.69, 118.49, 116.02, 113.15, 105.44, 100.75, 66.64, 





































2-(benzyloxy)-1,3-dimethoxybenzene lactone 15f. Using 2-(benzyloxy)-1,3-dimethoxybenzene 
14f (0.100 g, 0.199 mmol) as the starting material, the above general procedure afforded 2-
(benzyloxy)-1,3-dimethoxybenzene lactone 15f (0.010 g, 0.020 mmol, 10%) as an off-white 
powder: 1H NMR (400 MHz, (CD3)2CO) δ 9.28 (s, 1H), 7.70 (s, 1H), 7.60 – 7.54 (m, 2H), 7.37 
(tt, J = 8.1, 1.7 Hz, 2H), 7.33 – 7.28 (m, 1H), 7.13 (s, 1H), 6.67 (s, 2H), 5.38 (s, 2H), 5.09 (s, 
2H), 4.00 (s, 3H), 3.82 (s, 6H), 3.72 (s, 3H); 13C NMR (400 MHz, (CD3)2CO) δ 170.17, 154.15, 
152.21, 151.29, 145.64, 139.56, 137.45, 132.18, 132.08, 130.95, 128.98, 128.86, 128.38, 124.47, 
122.80, 119.72, 109.24, 107.02, 101.29, 75.11, 66.96, 56.59, 56.12, 55.80; HRMS-ESI calcd for 
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13C NMR (400 MHz, (CD3)2CO) 
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